Corbus Pharmaceuticals Holdings IncFind Ratings Reports
CORBUS PHARMACEUTICALS HLDGS's gross profit margin for the third quarter of its fiscal year 2020 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its subsector. CORBUS PHARMACEUTICALS HLDGS is extremely liquid. Currently, the Quick Ratio is 2.01 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
During the same period, stockholders' equity ("net worth") has remained virtually unchanged only decreasing by 1.40% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY20||Q3 FY19|
|Net Sales ($mil)||1.23||2.59|
|Net Income ($mil)||-34.9||-20.79|
|Balance Sheet||Q3 FY20||Q3 FY19|
|Cash & Equiv. ($mil)||82.22||54.85|
|Total Assets ($mil)||95.84||68.13|
|Total Debt ($mil)||26.18||8.33|
|Profitability||Q3 FY20||Q3 FY19|
|Gross Profit Margin||-2743.38||-962.9|
|Return on Assets||-134.84||-91.26|
|Return on Equity||-442.22||-209.78|
|Debt||Q3 FY20||Q3 FY19|
|Share Data||Q3 FY20||Q3 FY19|
|Shares outstanding (mil)||82.21||64.67|
|Div / share||0.0||0.0|
|Book value / share||0.36||0.46|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||5718155.0||4761192.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Conducting a second comparison, its price-to-book ratio of 4.89 indicates a premium versus the S&P 500 average of 4.02 and a significant discount versus the subsector average of 11.72. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, CORBUS PHARMACEUTICALS HLDGS proves to trade at a discount to investment alternatives.
|CRBP NM||Peers 33.50||CRBP NM||Peers 102.28|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
CRBP's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
CRBP's P/CF is negative making the measure meaningless.
|CRBP NM||Peers 21.30||CRBP NA||Peers 0.70|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
CRBP's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|CRBP 4.89||Peers 11.72||CRBP -75.49||Peers 5.00|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CRBP is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, CRBP is expected to significantly trail its peers on the basis of its earnings growth rate.
|CRBP 24.45||Peers 1929.85||CRBP -83.52||Peers 699.03|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CRBP is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
CRBP significantly trails its peers on the basis of sales growth.